← All trials
NCT04012138
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- Oct 2, 2021
- Completion date
- Apr 2, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 525
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of NantesLead sponsor
- University of LorraineOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of AngersOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of GrenobleOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
- University Hospital, ToursOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- CHU Louis MourierOverall official - principal investigator
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
- Hospital AvicenneOverall official - principal investigator
- Agen HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.